Docoh
Loading...

MRSN Mersana Therapeutics

News

From Benzinga Pro
Mersana Therapeutics Outlines 2022 Strategic Priorities, Milestones
7 Jan 22
Biotech, News, Guidance, FDA, General
UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in platinum-sensitive ovarian
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
5 Jan 22
Biotech, News, Penny Stocks, Guidance, Financing, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B
30 Nov 21
Biotech, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Synaffix B.V. has expanded its license agreement with Mersana Th
Mersana Therapeutics's Return On Capital Employed Insights
10 Nov 21
Earnings
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 11.17%, resulting in a loss of $45.39 million.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
9 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Mersana Therapeutics Q3 EPS $(0.63) Misses $(0.58) Estimate
9 Nov 21
Earnings, News
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent. This is a 90.91 percent decrease over losses of $(0.33) per share
Earnings Scheduled For November 9, 2021
9 Nov 21
Earnings, M&A, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

Press releases

From Benzinga Pro
Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
5 Jan 22
News, Health Care, Press Releases
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates
Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
30 Nov 21
Press Releases
AMSTERDAM, Nov. 30, 2021 /PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class
Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
9 Nov 21
Earnings, Press Releases
Reported updated data from the UpRi ovarian cancer expansion cohort further bolstering confidence in UPLIFT registration strategyIntroduced UP-NEXT, a Phase 3 study of UpRi monotherapy maintenance in platinum-sensitive
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2021 Financial Results and Business Updates
2 Nov 21
News, Health Care, Press Releases
CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 Oct 21
Health Care, Markets, Press Releases
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates